BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22028172)

  • 1. Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma.
    Murakami M; Fujimaki T; Asano S; Nakaguchi H; Yamada SM; Hoya K; Yamazaki K; Ishida Y; Matsuno A
    Yonsei Med J; 2011 Nov; 52(6):1031-4. PubMed ID: 22028172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.
    Adachi J; Mishima K; Wakiya K; Suzuki T; Fukuoka K; Yanagisawa T; Matsutani M; Sasaki A; Nishikawa R
    J Neurooncol; 2012 Mar; 107(1):147-53. PubMed ID: 21968944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Wong ET; Tishler R; Barron L; Wu JK
    Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.
    Makino K; Nakamura H; Hide T; Kuratsu J
    J Neurooncol; 2012 Jan; 106(1):155-60. PubMed ID: 21720808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
    Enting RH; Demopoulos A; DeAngelis LM; Abrey LE
    Neurology; 2004 Sep; 63(5):901-3. PubMed ID: 15365145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.
    Santisteban M; Nieto Y; De la Cruz S; Aristu J; Zubieta JL; Fernández Hidalgo O
    Clin Transl Oncol; 2007 Jul; 9(7):465-7. PubMed ID: 17652061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.
    Nayak L; Abrey LE; Drappatz J; Gilbert MR; Reardon DA; Wen PY; Prados M; Deangelis LM; Omuro A;
    Leuk Lymphoma; 2013 Jan; 54(1):58-61. PubMed ID: 22656234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.
    Jiang X; Reardon DA; Desjardins A; Vredenburgh JJ; Quinn JA; Austin AD; Herndon JE; McLendon RE; Friedman HS
    J Neurooncol; 2013 Aug; 114(1):135-40. PubMed ID: 23686298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
    Yamanaka R
    Brain Nerve; 2009 Oct; 61(10):1155-64. PubMed ID: 19882942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
    Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
    Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide.
    Wong SF; Gan HK; Cher L
    J Clin Neurosci; 2012 Nov; 19(11):1501-5. PubMed ID: 22995759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
    Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL
    Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
    del Rio MS; Choquet S; Hoang-Xuan K; Glaisner S; Fourme E; Janvier M; Soussain C
    J Neurooncol; 2011 Nov; 105(2):409-14. PubMed ID: 21656329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab maintenance therapy in central nervous system lymphoma?
    Murawski N; Pfreundschuh M
    Leuk Lymphoma; 2009 Oct; 50(10):1555-6. PubMed ID: 19757314
    [No Abstract]   [Full Text] [Related]  

  • 15. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status.
    Kurzwelly D; Glas M; Roth P; Weimann E; Lohner H; Waha A; Schabet M; Reifenberger G; Weller M; Herrlinger U
    J Neurooncol; 2010 May; 97(3):389-92. PubMed ID: 19841864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL).
    Salamoon M; Hussein T; Kenj M; Bachour M
    Med Oncol; 2013 Dec; 30(4):690. PubMed ID: 23959450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Pitini V; Arrigo C; Righi M
    Cancer; 2004 Dec; 101(12):2900-1; author reply 2901-2. PubMed ID: 15529311
    [No Abstract]   [Full Text] [Related]  

  • 19. (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.
    Collignon A; Houillier C; Ahle G; Chinot O; Choquet S; Schmitt A; Agape P; Soussain C; Hoang-Xuan K; Tabouret E
    Ann Hematol; 2019 Apr; 98(4):915-922. PubMed ID: 30535802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.
    Glass J; Won M; Schultz CJ; Brat D; Bartlett NL; Suh JH; Werner-Wasik M; Fisher BJ; Liepman MK; Augspurger M; Bokstein F; Bovi JA; Solhjem MC; Mehta MP
    J Clin Oncol; 2016 May; 34(14):1620-5. PubMed ID: 27022122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.